Aurinia Pharmaceuticals Inc. provided earning guidance for 2022. For fiscal year 2022, the Company maintains its net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150 to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.285 USD | +1.44% | -5.72% | -41.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.38% | 743M | |
+9.92% | 118B | |
+10.24% | 106B | |
-11.32% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.62% | 15.97B | |
+6.88% | 14.03B | |
+18.22% | 11.67B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Earning Guidance for 2022